Dr. Suresh Nair | Source | Physician In Chief, Topper Cancer Institute at Lehigh Valley Health Network ...
Dr. Suresh Nair
Suresh Nair, MD, is Physician in Chief at Lehigh Valley Topper Cancer Institute. Dr. Nair is the Chair of American Board of Internal Medicine’s Medical Oncology Board. His areas of focus include: Melanoma, Renal (Kidney) cancer, Sarcoma, Immunotherapy and Precision Oncology. Dr. Nair is also active in leading-edge cancer research including clinical trials through relationships with Memorial Sloan Kettering (MSK), NCORP (NCI Community Oncology Research Program), Strata Oncology and other clinical partnerships.
-
Lehigh Valley Health Network (LVHN) (https://www.lvhn.org/)
Physician In Chief, Topper Cancer Institute at Lehigh Valley Health Network
-
Insights into cellular therapies for cancer treatment
We had the privilege of discussing the opportunities of various cell therapies with Dr Suresh Nair, Physician in Chief, who elucidates how Lehigh Valley Topper Cancer Institute is directing research towards better treatments, better outcomes, and better patient experience at a lower cost.
Article -
Colon, lung cancer: Cardiorespiratory fitness may lower risk
Higher cardiorespiratory fitness may help reduce the incidence of colon and lung cancer in men, a new study suggests.
Article -
Two new cancer pills show ‘unprecedented’ results in boosting survival rates and preventing recurrence
Potentially “practice-changing" new breast and lung cancer treatments were announced at the American Society of Clinical Oncology's annual meeting this week in Chicago. Here are details.
Article
-
"At Lehigh Valley Topper Cancer Institute, we are dedicated to personalized care through precision medicine. We not only offer advanced treatments and access to over 150 clinical trials, but also opportunities for molecular profiling for most of our patients. That is the future of cancer care, and it’s already here in the Lehigh Valley.”
-
“Molecular testing allows us to look for genetic mutations in cancer cells that we can target with specific treatments,”
-
“With research, you can’t guarantee a 100% cure. This is still preliminary but it’s a chance for the patients who are eligible to have a less invasive type of treatment. Potentially they’ll still need monitoring, but potentially they’ll be avoiding surgery, chemo or radiation,”
